Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 12, 2016, Pages

  Zhu, Ying ^a   Zhang, Ting ^b   Xu, Gezhi ^b   Peng, Lijun ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; VERTEPORFIN; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADVERSE DRUG REACTION; CENTRAL MACULAR THICKNESS; CLINICAL OUTCOME; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYOPIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHAM PROCEDURE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DEGENERATIVE MYOPIA; META ANALYSIS; PHOTOCHEMOTHERAPY; RETINA MACULA LUTEA; SURGERY;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; HUMANS; LASER COAGULATION; MACULA LUTEA; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85006274520     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011160.pub2     Document Type: Review

References (69)

1. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomized controlled trial. American Journal of Ophthalmology 2010;149(3):458-64. [4489315]
2. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012;32(8):1539-46. [4489317]
3. Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study. Ophthalmology 2015;122(6):1220-7. [4489319]
4. Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Archives of Ophthalmology 2010;128(4):437-42. [4489321]
5. Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121(3):682-92. [4489323]
6. Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, Gomez-Ulla F, Garcia-Arumi J, Garcia-Layana A, et al. Myopic choroidal neovascularization. Ophthalmology 2011;118(12):2521-3. [4489325]
7. Ruiz-Moreno JM, Lopez-Galvez MI, Montero Moreno JA, Pastor Jimeno JC. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. Ophthalmology 2013;120(7):1510-1. [4489326]
8. Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011;118(1):111-8. [4489328]
9. Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 2013;120(9):1944-5. [4489330]
10. Saviano S, Piermarocchi R, Leon PE, Mangogna A, Zanei A, Cavarzeran Sc F, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. International Journal of Ophthalmology 2014;7(2):335-9. [4489332]
11. NCT01716026 Establishment of the initial protocol with intravitreal bevacizumab for the treatment of choroidal neovascularization associated with high myopia:3 vs 1. clinicaltrials.gov/ct2/show/NCT01716026 Date first received: 25 October 2012. [4489334]
12. NCT01809223 The safety and efficacy of conbercept in the treatment of choroidal neovascularization (CNV) secondary to high myopia. clinicaltrials.gov/ct2/show/NCT01809223 Date first received: 11 March 2013. [4489336]
13. NCT01922102 A 12-month, phase III, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two individualized regimens of 0.5mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. clinicaltrials.gov/ct2/show/NCT01922102 Date first received: 12 August 2013. [4489338]
14. Adamis AP, & Miller JW, & Bernal MT, & D'Amico DJ, & Folkman J, & Yeo TK, & et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. American Journal of Ophthalmology 1994;118(4):445-50.
15. Aiello LP, & Avery RL, & Arrigg PG, & Keyt BA, & Jampel HD, & Shah ST, & et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994;331(22):1480-7.
16. Baba T, & Kubota-Taniai M, & Kitahashi M, & Okada K, & Mitamura Y, & Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. British Journal of Ophthalmology 2010;94(7):864-70.
17. Battaglia Parodi M, Iacono P, Bandello F. Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia. Developments in Ophthalmology 2010;46:73-83.
18. Bennett MD, & Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefe's Archive for Clinical and Experimental Ophthalmology 2007;245(6):903-5.
19. Blinder KJ, & Blumenkranz MS, & Bressler NM, & Bressler SB, & Donato G, & Lewis H, & et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report No. 3. Ophthalmology 2003;110(4):667-73.
20. Boyd SR, & Zachary I, & Chakravarthy U, & Allen GJ, & Wisdom GB, & Cree IA, & et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Archives of Ophthalmology 2002;120(12):1644-50.
21. Brancato R, & Pece A, & Avanza P, & Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10(4):239-43.
22. Brown DM, & Heier JS, & Ciulla T, & Benz M, & Abraham P, & Yancopoulos G, & et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011;118(6):1089-97.
23. CATT Research Group, & Martin DF, & Maguire MG, & Ying GS, & Grunwald JE, & Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011;364(20):1897-908.
24. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98.
25. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29(8):1062-6.
26. Costa RA, & Jorge R, & Calucci D, & Cardillo JA, & Melo LA Jr, & Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Investigative Ophthalmology and Visual Science 2006;47(10):4569-78.
27. Giansanti F, Virgili G, Donati MC, Giuntoli M, Pieretti G, Abbruzzese G, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularisation with pathologic myopia. Retina 2012;32(8):1547-52.
28. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
29. Gragoudas ES, & Adamis AP, & Cunningham ET Jr, & Feinsod M, & Guyer DR, & VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004;351(27):2805-16.
30. Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye 2010;24(2):203-13.
31. Hamelin N, & Glacet-Bernard A, & Brindeau C, & Mimoun G, & Coscas G, & Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. American Journal of Ophthalmology 2002;133(4):530-6.
32. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncology 2004;5(5):292-302.
33. Hawkins BS, & Miskala PH, & Bass EB, & Bressler NM, & Childs AL, & Mangione CM, & et al. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10. Archives of Ophthalmology 2004;122(11):1616-28.
34. Hayashi K, & Ohno-Matsui K, & Shimada N, & Moriyama M, & Kojima A, & Hayashi W, & et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010;117(8):1595-611.
35. Hayashi K, & Shimada N, & Moriyama M, & Hayashi W, & Tokoro T, & Ohno-Matsui K. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012;32(4):687-95.
36. Higgins JP, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
37. Hsiang HW, & Ohno-Matsui K, & Shimada N, & Hayashi K, & Moriyama M, & Yoshida T, & et al. Clinical characteristics of posterior staphyloma in eyes with pathologic myopia. American Journal of Ophthalmology 2008;146(1):102-10.
38. Ikuno Y, & Sayanagi K, & Soga K, & Sawa M, & Gomi F, & Tsujikawa M, & et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 2008;28(8):1124-31.
39. Ikuno Y, & Nagai Y, & Matsuda S, & Arisawa A, & Sho K, & Oshita T, & et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. American Journal of Ophthalmology 2010;149(1):140-6.
40. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411.
41. Iwase A, & Araie M, & Tomidokoro A, & Yamamoto T, & Shimizu H, & Kitazawa Y, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology 2006;113(8):1354-62.
42. Johnson DA, & Yannuzzi LA, & Shakin JL, & Lightman DA. Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 1998;18(2):118-24.
43. Kamei M, & Tano Y, & Yasuhara T, & Ohji M, & Lewis H. Macular translocation with chorioscleral outfolding: 2-year results. American Journal of Ophthalmology 2004;138(4):574-81.
44. Kvanta A, & Algvere PV, & Berglin L, & Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science 1996;37(9):1929-34.
45. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Annals of Pharmacotherapy 2007;41(4):614-25.
46. Michels S, & Rosenfeld PJ, & Puliafito CA, & Marcus EN, & Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112(6):1035-47.
47. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI:10.1002/14651858.CD011230.pub2]
48. Ng DS, Kwok AK, Chan CW. Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clinical and Experimental Ophthalmology 2012;40(1):e98-e110.
49. Nguyen QD, & Shah S, & Tatlipinar S, & Do DV, & Anden EV, & Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. British Journal of Ophthalmology 2005;89(10):1368-70.
50. Ohno-Matsui K, & Yoshida T, & Futagami S, & Yasuzumi K, & Shimada N, & Kojima A, & et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. British Journal of Ophthalmology 2003;87(5):570-3.
51. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
52. Rosenfeld PJ, & Brown DM, & Heier JS, & Boyer DS, & Kaiser PK, & Chung CY, & et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1419-31.
53. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. British Journal of Ophthalmology 2001;85(9):1041-3.
54. Ruiz-Moreno JM, & Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefe's Archive for Clinical and Experimental Ophthalmology 2010;248(7):937-41.
55. Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, Gomez-Ulla F, Garcia-Arumi J, Garcia-Layana A, et al. Myopic choroidal neovascularization. Ophthalmology 2011;118(12):2521-3.
56. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI:10.1002/14651858.CD005139.pub3]
57. Sperduto RD, & Seigel D, & Roberts J, & Rowland M. Prevalence of myopia in the United States. Archives of Ophthalmology 1983;101(3):405-7.
58. Sun XD, Xu WQ, Rosenfeld PJ. Therapeutic efficacy and safety of off-label use of bevacizumab for the treatment of neovascular diseases of the eye. Chinese Journal of Ophthalmology 2008;44(3):281-4.
59. Takeuchi K, & Kachi S, & Iwata E, & Ishikawa K, & Terasaki H. Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration. Eye 2012;26(1):51-60.
60. Uemura A, & Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Archives of Ophthalmology 2000;118(3):344-50.
61. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report No. 1. Ophthalmology 2001;108(5):841-52.
62. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI:10.1002/14651858.CD007419.pub4]
63. Voykov B, & Gelisken F, & Inhoffen W, & Voelker M, & Bartz-Schmidt KU, & Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?. Graefe's Archive for Clinical and Experimental Ophthalmology 2010;248(4):543-50.
64. Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 2013;33(7):1375-92.
65. Wong TY, & Foster PJ, & Hee J, & Ng TP, & Tielsch JM, & Chew SJ, & et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Investigative Ophthalmology and Visual Science 2000;41(9):2486-94.
66. Xu L, & Wang Y, & Li Y, & Wang Y, & Cui T, & Li J, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006;113(7):1134.e1-11.
67. Yamamoto I, & Rogers AH, & Reichel E, & Yates PA, & Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. British Journal of Ophthalmology 2007;91(2):157-60.
68. Yoshida T, & Ohno-Matsui K, & Yasuzumi K, & Kojima A, & Shimada N, & Futagami S, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110(7):1297-305.
69. Zhu Y, Zhang T, Xu G, Peng L. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD011160]